Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Saroglitazar improves liver health and glycemic control in type 2 diabetes
Last updated July 22, 2026
Key finding
NFS decreased by -0.57 (p = 0.026)
This study compared the effects of Saroglitazar and Pioglitazone on liver health and blood sugar control in patients with Type 2 Diabetes and liver disease, finding significant improvements in certain measures.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the effects of Saroglitazar and Pioglitazone on liver health and blood sugar control in patients with Type 2 Diabetes and liver disease, finding significant improvements in certain measures.
Clinical relevance
These findings highlight the potential of Saroglitazar as an effective treatment option for patients with Type 2 Diabetes and liver disease. Improved glycemic control and liver health can lead to better overall outcomes for patients, reducing the risk of complications associated with both conditions.
Keep in mind
The study included a limited sample size, which may affect generalizability. Some outcomes did not reach statistical significance, indicating uncertainty in effectiveness. The study did not assess long-term effects beyond the intervention period.
Published in
Journal Reference
Publication details and source links for this paper.
Alexander M, John RA, Dayanidhi M, et al. Comparative Effects of Saroglitazar and Pioglitazone on Hepatic Steatosis and Glycemic Control in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Cureus. 2025;17(12):e100002. doi:10.7759/cureus.100002
Main Effects
HbA1c dropped by 0.81% (p<0.0001) indicating improved glycemic control.
BMI decreased by -3.32 kg/m² (p = 0.006) suggesting weight loss.
Non-alcoholic fatty liver disease fibrosis score (NFS) decreased by -0.57 (p = 0.026) indicating improved liver health.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Pioglitazone, Saroglitazar 4 mg and BMI, Controlled attenuation parameter, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
Pioglitazone
Primary outcomes
- BMI
- Controlled attenuation parameter
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
10
Evidence pairs
496
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Thiazolidinediones and HbA1c
Related evidence
Evidence relationship
Thiazolidinediones and Body Mass Index
Save evidence
Evidence topic
HbA1c Reduction
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Controlled attenuation parameter
Pioglitazone → Controlled attenuation parameter
Pioglitazone → Controlled attenuation parameter
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerControlled attenuation parameter
Saroglitazar 4 mg → Controlled attenuation parameter
Saroglitazar 4 mg → Controlled attenuation parameter
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerLiver stiffness measure
Saroglitazar 4 mg → Liver stiffness measure
Saroglitazar 4 mg → Liver stiffness measure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerNAFLD Fibrosis Score
Saroglitazar 4 mg → NAFLD Fibrosis Score
Saroglitazar 4 mg → NAFLD Fibrosis Score
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- HbA1c levels significantly decreased by 0.81%, showing improved blood sugar control.
- BMI reduction of -3.32 kg/m² suggests effective weight management.
- NFS improvement of -0.57 indicates potential benefits for liver health.
Who this applies to
- Adults diagnosed with Type 2 Diabetes.
- Patients with metabolic dysfunction-associated steatotic liver disease.
Keep in Mind
- Results may not be applicable to populations outside the study sample.
- Further research is needed to confirm long-term benefits.
- Statistical significance does not always imply clinical relevance.
Between the Lines
- The study included a limited sample size, which may affect generalizability.
- Some outcomes did not reach statistical significance, indicating uncertainty in effectiveness.
- The study did not assess long-term effects beyond the intervention period.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Thiazolidinediones and HbA1c, Thiazolidinediones and Body Mass Index.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Thiazolidinediones → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 4 studies
View evidenceMedications
Thiazolidinediones → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
4 studies
outcome_hubMeasures HbA1c as a key outcome.
Thiazolidinediones Evidence Hub
All studies on Thiazolidinediones
4 studies
intervention_hubContributes to Thiazolidinediones evidence base.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
2 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Pioglitazone and HbA1c
Intervention: PioglitazoneOutcome: HbA1c
4 results
All studies on Pioglitazone and BMI
Intervention: PioglitazoneOutcome: BMI
2 results
All studies on Pioglitazone
Intervention: Pioglitazone
4 results
All studies measuring HbA1c
Outcome: HbA1c
4 results
All studies measuring BMI
Outcome: BMI
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Thiazolidinediones improve HbA1c?
Strong Evidence
Thiazolidinediones appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Thiazolidinediones affect body mass index?
Moderate Evidence
Thiazolidinediones appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Pioglitazone improve controlled attenuation parameter?
Moderate Evidence
Pioglitazone may improve Controlled attenuation parameter.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Controlled attenuation parameter
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Pioglitazone improve liver stiffness measure?
Moderate Evidence
Current evidence does not show a clear benefit of Pioglitazone for Liver stiffness measure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Liver stiffness measure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
GLP-1 agonists reduce heart fat thickness in diabetes.Semaglutide improves liver health and lipid levels in diabetesEmpagliflozin and Pioglitazone improve heart function in diabetes patientsAdding medications improves blood sugar control in diabetes patients.Dietary supplements may lower diabetes risk in prediabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.